These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 20454585)

  • 1. Application of adoptive T-cell therapy using tumor antigen-specific T-cell receptor gene transfer for the treatment of human leukemia.
    Ochi T; Fujiwara H; Yasukawa M
    J Biomed Biotechnol; 2010; 2010():521248. PubMed ID: 20454585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a Wilms' tumor antigen-specific T-cell receptor for clinical trials: engineered patient's T cells can eliminate autologous leukemia blasts in NOD/SCID mice.
    Xue SA; Gao L; Thomas S; Hart DP; Xue JZ; Gillmore R; Voss RH; Morris E; Stauss HJ
    Haematologica; 2010 Jan; 95(1):126-34. PubMed ID: 19679884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T-cell receptor gene transfer for treatment of leukemia.
    Heemskerk MH; Griffioen M; Falkenburg JH
    Cytotherapy; 2008; 10(2):108-15. PubMed ID: 18368589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel adoptive T-cell immunotherapy using a WT1-specific TCR vector encoding silencers for endogenous TCRs shows marked antileukemia reactivity and safety.
    Ochi T; Fujiwara H; Okamoto S; An J; Nagai K; Shirakata T; Mineno J; Kuzushima K; Shiku H; Yasukawa M
    Blood; 2011 Aug; 118(6):1495-503. PubMed ID: 21673345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Redirected T cell-based antileukemia adoptive immunotherapy using tumor antigen-specific TCR gene transfer].
    Fujiwara H
    Rinsho Ketsueki; 2014 Jun; 55(6):657-69. PubMed ID: 24975335
    [No Abstract]   [Full Text] [Related]  

  • 6. Antigen-specific cellular immunotherapy of leukemia.
    Van Driessche A; Gao L; Stauss HJ; Ponsaerts P; Van Bockstaele DR; Berneman ZN; Van Tendeloo VF
    Leukemia; 2005 Nov; 19(11):1863-71. PubMed ID: 16121214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer immunotherapy with lymphocytes genetically engineered with T cell receptors for solid cancers.
    Chen L; Qiao D; Wang J; Tian G; Wang M
    Immunol Lett; 2019 Dec; 216():51-62. PubMed ID: 31597088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospects and limitations of T cell receptor gene therapy.
    Coccoris M; de Witte MA; Schumacher TN
    Curr Gene Ther; 2005 Dec; 5(6):583-93. PubMed ID: 16457648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alphabeta T-cell receptor engineered gammadelta T cells mediate effective antileukemic reactivity.
    van der Veken LT; Hagedoorn RS; van Loenen MM; Willemze R; Falkenburg JH; Heemskerk MH
    Cancer Res; 2006 Mar; 66(6):3331-7. PubMed ID: 16540688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3.
    Lu YC; Parker LL; Lu T; Zheng Z; Toomey MA; White DE; Yao X; Li YF; Robbins PF; Feldman SA; van der Bruggen P; Klebanoff CA; Goff SL; Sherry RM; Kammula US; Yang JC; Rosenberg SA
    J Clin Oncol; 2017 Oct; 35(29):3322-3329. PubMed ID: 28809608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy.
    Wu F; Zhang W; Shao H; Bo H; Shen H; Li J; Liu Y; Wang T; Ma W; Huang S
    Cancer Lett; 2013 Oct; 339(2):195-207. PubMed ID: 23791878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene-transduced human T cells.
    Xue SA; Gao L; Hart D; Gillmore R; Qasim W; Thrasher A; Apperley J; Engels B; Uckert W; Morris E; Stauss H
    Blood; 2005 Nov; 106(9):3062-7. PubMed ID: 16020516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimization of T-cell Reactivity by Exploiting TCR Chain Centricity for the Purpose of Safe and Effective Antitumor TCR Gene Therapy.
    Ochi T; Nakatsugawa M; Chamoto K; Tanaka S; Yamashita Y; Guo T; Fujiwara H; Yasukawa M; Butler MO; Hirano N
    Cancer Immunol Res; 2015 Sep; 3(9):1070-81. PubMed ID: 25943533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Requisite considerations for successful adoptive immunotherapy with engineered T-lymphocytes using tumor antigen-specific T-cell receptor gene transfer.
    Ochi T; Fujiwara H; Yasukawa M
    Expert Opin Biol Ther; 2011 Jun; 11(6):699-713. PubMed ID: 21413911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T-cell receptor gene therapy of established tumors in a murine melanoma model.
    Abad JD; Wrzensinski C; Overwijk W; De Witte MA; Jorritsma A; Hsu C; Gattinoni L; Cohen CJ; Paulos CM; Palmer DC; Haanen JB; Schumacher TN; Rosenberg SA; Restifo NP; Morgan RA
    J Immunother; 2008 Jan; 31(1):1-6. PubMed ID: 18157006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antileukemia multifunctionality of CD4(+) T cells genetically engineered by HLA class I-restricted and WT1-specific T-cell receptor gene transfer.
    Fujiwara H; Ochi T; Ochi F; Miyazaki Y; Asai H; Narita M; Okamoto S; Mineno J; Kuzushima K; Shiku H; Yasukawa M
    Leukemia; 2015 Dec; 29(12):2393-401. PubMed ID: 26104661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PRAME peptide-specific CD8
    Matko S; Manderla J; Bonsack M; Schmitz M; Bornhauser M; Tonn T; Odendahl M
    Eur J Immunol; 2018 Aug; 48(8):1400-1411. PubMed ID: 29738081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy of acute leukemia by chimeric antigen receptor-modified lymphocytes using an improved Sleeping Beauty transposon platform.
    Magnani CF; Turazzi N; Benedicenti F; Calabria A; Tenderini E; Tettamanti S; Giordano Attianese GM; Cooper LJ; Aiuti A; Montini E; Biondi A; Biagi E
    Oncotarget; 2016 Aug; 7(32):51581-51597. PubMed ID: 27323395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Promise of Chimeric Antigen Receptor T-Cell Therapy.
    Frey NV; Porter DL
    Oncology (Williston Park); 2016 Oct; 30(10):880-8, 890. PubMed ID: 27744645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting cancers through TCR-peptide/MHC interactions.
    He Q; Jiang X; Zhou X; Weng J
    J Hematol Oncol; 2019 Dec; 12(1):139. PubMed ID: 31852498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.